---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000875"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2022-02-08T23:59:59+00:00"
generated_at: "2026-06-27T09:56:06.559381+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enanta Q1 net loss $30.1M; plans to start EDP-235 Phase 1 this month

## Summary
- Net loss of $30.1M ($1.48 per diluted share) vs $8.3M loss in prior-year quarter.
- Royalty revenue from MAVYRET/MAVIRET was $27.6M, down from $31.7M YoY.
- R&D expenses rose to $48.5M from $36.7M due to manufacturing for virology programs.
- Cash and marketable securities $347.7M; expects sufficient runway for at least two years.
- EDP-235 (oral COVID-19 treatment) Phase 1 dosing begins Feb 2022; RSVP topline data expected Q2 2022.

## SEC filing metadata
- accession: 0000950170-22-000875
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2022-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017022000875/0000950170-22-000875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017022000875/enta-20220208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000875
- JSON: https://secwatch.observer/filing/0000950170-22-000875.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.